Full Press Release Details
Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)
TIKVA, Israel, May 20, 2019 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of
proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that the International
Liver Cancer Association (ILCA) has accepted Can-Fite's abstract describing the latest data from the Company's Phase
II Liver Cancer study of Namodenoson for an oral presentation at its annual conference. The oral presentation titled "The
Safety and Efficacy of Namodenoson in the Second Line Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients with Underlying
Child-Pugh B (CPB) Liver Cirrhosis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled" will be delivered on September
22, 2019 during the Novel Targets and Prognostic Markers Session from 11:00 am to 12:30 pm. The ILCA's 13th Annual
Conference will take place from September 20 to 22, 2019 in Chicago, Illinois.
ILCA is the only international organization devoted exclusively to liver cancer research for experts from all related disciplines.
Its mission is to lead a global community of physicians, scientists and allied professionals through education and research with
the goal to better prevent and treat liver cancer.
is a very prestigious conference that brings together the leading thought leaders, researchers, and physicians in the treatment
of liver cancer. Governing members of the ILCA thoroughly research each abstract submission and select those that are most relevant
to the advancement of treating liver cancer. We are pleased that the selection committee sees the potential of Namodenoson as
a treatment for advanced liver cancer patients with severe liver dysfunction. Based on both safety and efficacy in this Phase
II study, Can-Fite is preparing a Phase III trial," stated Can-Fite CEO Pnina Fishman.
is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson
is being evaluated as a second line treatment for hepatocellular carcinoma, with a recently completed Phase II trial and planned
Phase III trial in this indication. The drug is currently in an ongoing Phase II trial as a treatment for non-alcoholic fatty
liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly expressed in diseased cells whereas low expression
is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.
Can-Fite BioPharma Ltd.
BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology
that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction.
The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's
liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of
liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted
Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food
and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate,
and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical
studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These
drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date. For more information
please visit: www.can-fite.com.
press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among
other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations,
strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking
statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe,"
"expect," "intend," "plan," "may," "should" or "anticipate"
or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate
strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various
filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the
approval of one of Can-Fite's authorized executive officers. Forward-looking statements relate to anticipated or expected
events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual
results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could
cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated in such forward-looking
statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking
statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and
our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working
capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate
development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical
studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory
filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability
to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model
and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for
intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual
property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political
and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fite's filings with the
SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are
highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation
to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.